CurrentCignaPolicy IP0164

Gaucher Disease - Enzyme Replacement Therapy - Vpriv

Defines Cigna coverage and prior authorization criteria for Vpriv (velaglucerase alfa) for treatment of Gaucher disease (Types 1 and 3) and specifies prescribing and dosing requirements for affected patients and providers.

Policy Summary

PayerCigna

PolicyGaucher Disease - Enzyme Replacement Therapy - Vpriv

Policy CodePolicy IP0164

Change TypeOperational updates, material changes to age and dosing

Effective Date

Next Review DateJun 15, 2025

Key ActionPrior authorization is required for Vpriv and approvals are provided for 1 year when criteria are met and Vpriv is prescribed by or in consultation with an appropriate specialist.

SourceLink

POLICY UPDATE CHANGES

Policy name changed to 'Gaucher Disease - Enzyme Replacement Therapy - Vpriv' and the Condition name 'Gaucher Disease - Type 1' was qualified with a note that Type 1 is also referred to as non-neuronopathic disease.

Added age ≥ 4 years as a condition for approval.

Added dosing information and maximum per-dose limits for Type 1 and Type 3 indications.

Removed prior statement limiting coverage for type 3 Gaucher disease to cases resulting in at least one of anemia, thrombocytopenia, bone disease, hepatomegaly, or splenomegaly.

2Gaucher disease phenotypes addressed

≥4 yrsMinimum patient age for approval

60 U/kgMax dose per administration (Type 1)

Policy Summary

PayerCigna

PolicyGaucher Disease - Enzyme Replacement Therapy - Vpriv

Policy CodePolicy IP0164

Change TypeOperational updates, material changes to age and dosing

Effective Date

Next Review DateJun 15, 2025

Key ActionPrior authorization is required for Vpriv and approvals are provided for 1 year when criteria are met and Vpriv is prescribed by or in consultation with an appropriate specialist.

SourceLink

On This Page

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Coverage Criteria for Vpriv (velaglucerase alfa)

Concomitant use of Vpriv with other therapies approved for Gaucher disease has not been evaluated. Examples of other approved therapies include eliglustat (Cerdelga), taliglucerase alfa (Elelyso), imiglucerase (Cerezyme), and miglustat (Zavesca). Because combination therapy has not been assessed for safety or effectiveness in the evidence reviewed for this policy, concomitant administration with other approved Gaucher treatments is not supported by this policy.

Vpriv for any other use is considered not medically necessary. The policy states that uses outside the specified Type 1 and Type 3 criteria are not covered; this includes indications or clinical scenarios not described in the approved and supportive-evidence sections of the policy.

Use of Vpriv for indications other than the specified Type 1 and Type 3 criteria is considered not medically necessary. This includes concomitant therapy with other approved Gaucher disease treatments (not evaluated) and any other clinical uses not explicitly listed in the policy’s covered indications.

Confirmation of Gaucher disease

Molecular testing is an accepted method to establish diagnosis for policy eligibility. Coverage is allowed when testing documents biallelic pathogenic variants in GBA.

Accepted Diagnostic Methods: Diagnosis confirmed by molecular genetic testing documenting biallelic pathogenic variants in the glucocerebrosidase (GBA) gene.

Molecular testing is an alternative to demonstration of deficient β-glucocerebrosidase activity in leukocytes or fibroblasts for purposes of meeting policy diagnostic requirements.

Coding, Age, and Dosing Information

Considered Medically Necessary (when criteria met)HCPCSCovered

J3385

Injection, velaglucerase alfa, 100 units

inv-07: Age

Minimum agePatient must be ≥ 4 years of age.

inv-08: Dose per administration (Type 1)

Type 1 dosing limitEach individual dose ≤ 60 U/kg administered intravenously no more frequently than once every 2 weeks.

inv-09: Dose per administration (Type 3)

Type 3 dosing limitEach individual dose ≤ 120 U/kg administered intravenously no more frequently than once every 2 weeks.

Prior Authorization and Documentation Requirements

Prior Authorization

Prior Authorization Required — Prior authorization is required for Vpriv

Prior Authorization is required for Vpriv. Approvals are provided for 1 year when criteria are met. Because of the specialized skills required for evaluation, diagnosis, and monitoring of patients treated with Vpriv, the medication must be prescribed by or in consultation with a geneticist, endocrinologist, metabolic disorder sub-specialist, or a physician who specializes in the treatment of lysosomal storage disorders.

Approval duration: 1 year when criteria are met
Prescriber requirement: geneticist, endocrinologist, metabolic disorder sub-specialist, or physician specialist

Denial Risk

Concomitant Therapy — Concomitant use with other approved Gaucher therapies has not been evaluated

Concomitant use of Vpriv with other therapies approved for Gaucher disease has not been evaluated. Such combination therapy is considered not medically necessary under this policy.

Patient Eligibility Requirements

No additional top-level eligibility requirements are specified in this policy beyond the specific Type 1 and Type 3 criteria detailed in the coverage criteria sections.

There are no further eligibility prerequisites (such as family history or prior testing nodes) listed as top-level requirements outside the documented diagnostic and provider conditions in the coverage criteria.

Key Definitions

inv-15: Type 1 Gaucher disease

DefinitionNon‑neuronopathic Gaucher disease (Type 1) — presents with splenomegaly, hepatomegaly, anemia, thrombocytopenia, and skeletal disease.

inv-16: Type 3 Gaucher disease

DefinitionChronic neuronopathic Gaucher disease (Type 3) — chronic neuronopathic form with neurological, hematologic, and visceral symptoms; enzyme replacement therapy improves systemic (hematologic and visceral) manifestations but not neurological manifestations.

Background on Gaucher Disease and Vpriv

Gaucher disease is an autosomal recessive lysosomal storage disorder caused by deficiency of the lysosomal enzyme β‑glucocerebrosidase, leading to accumulation of glucosylceramide in visceral organs. Type 1 (non‑neuronopathic) is the most common form and typically presents with splenomegaly, hepatomegaly, anemia, thrombocytopenia, and skeletal disease. Neuronopathic forms (Types 2 and 3) manifest earlier with neurological involvement; Type 3 is a chronic neuronopathic form with systemic and neurologic features. Diagnosis is established by demonstration of deficient enzyme activity in leukocytes or fibroblasts or by molecular genetic testing documenting biallelic pathogenic variants in the GBA gene.

Not Covered

Concomitant use of Vpriv with other therapies approved for Gaucher disease is considered not medically necessary. The policy notes that combination therapy has not been evaluated and explicitly lists examples of other approved agents (eliglustat, taliglucerase alfa, imiglucerase, miglustat) to which this restriction applies.

Documentation Required

Required Clinical Documentation — Documentation must demonstrate diagnosis per specified methods and other required items

Documentation must demonstrate the diagnosis of Gaucher disease by one of the following methods and include evidence of the clinical rationale for therapy. For Type 1 (non-neuronopathic) and Type 3 (chronic neuronopathic) Gaucher disease, diagnosis must be established by ONE of: 1) demonstration of deficient β-glucocerebrosidase activity in leukocytes or fibroblasts, OR 2) molecular genetic testing documenting biallelic pathogenic variants in the GBA gene. For Type 3, additional documentation that the medication is being used for management of impaired growth, hematologic, or visceral symptoms (and not for neurological manifestations) is required. Also include patient age (must be ≥ 4 years), dosing plan consistent with policy limits (Type 1: ≤ 60 U/kg IV no more frequently than every 2 weeks; Type 3: ≤ 120 U/kg IV no more frequently than every 2 weeks), and documentation that the prescriber is an appropriate specialist or that therapy is in consultation with one.

Diagnosis documentation: enzyme assay (leukocytes or fibroblasts) OR molecular genetic testing documenting biallelic pathogenic GBA variants
Age: patient ≥ 4 years
Type-specific documentation: For Type 3, documentation that treatment targets impaired growth, hematologic, or visceral symptoms and not neurological manifestations
Dosing limits: Type 1 ≤ 60 U/kg IV every ≥ 2 weeks; Type 3 ≤ 120 U/kg IV every ≥ 2 weeks
Prescriber requirement: prescribed by or in consultation with a geneticist, endocrinologist, metabolic disorder sub-specialist, or lysosomal storage disorder specialist
Note: receipt of sample product does not satisfy criteria for coverage